IP Library Granted Patent US 12,252,594
Granted Patent B2
US 12,252,594 · App. 16/729,179 · Granted Mar 18, 2025

Method of preparing a hydrogel product

Inventors: Lars Nord (Uppsala, SE); Hotan Mojarradi (Uppsala, SE); Johan Olsson (Bromma, SE)
Assignee: Galderma Holding SA
C08J3/075C08J3/24C08J2305/02C08J2305/10C08K5/1545
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,252,594
App. No.
16/729,179
Granted
Mar 18, 2025
Kind
B2
Abstract

A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, comprising the steps of: (a) providing a mixed solution of glycosaminoglycan molecules, a di- or multinucleophilic functional crosslinker, and a mononucleophilic functional graft chain; (b) activating carboxyl groups on the glycosaminoglycan molecules with a coupling agent to form activated glycosaminoglycan molecules; and (c) simultaneously crosslinking the activated glycosaminoglycan molecules and grafting the graft chain to the activated glycosaminoglycan molecules by reacting the nucleophiles with the activated carboxyl groups.

Claims (32)

1. A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, the method comprising:

(a) providing a mixed solution comprising glycosaminoglycan molecules, a di- or multinucleophilic functional crosslinker, and a mononucleophilic functional graft chain;

(b) activating carboxyl groups on the glycosaminoglycan molecules with a coupling agent to form activated glycosaminoglycan molecules; and

(c) simultaneously crosslinking the activated glycosaminoglycan molecules with the crosslinker and grafting the graft chain to the activated glycosaminoglycan molecules by reacting nucleophilic groups of the crosslinker and the graft chain with the activated carboxyl groups, wherein the coupling agent and free crosslinker are simultaneously present at a concentration ratio of about 125/0.6 to about 125/0.9.

2. The method according to claim 1 , wherein the glycosaminoglycan molecules are selected from the group consisting of hyaluronic acid, chondroitin, and chondroitin sulfate, and mixtures thereof.

3. The method according to claim 1 , wherein the crosslinker comprises a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.

4. The method according to claim 1 , wherein the nucleophilic groups of the crosslinker are selected from the group consisting of primary amine, hydrazine, hydrazide, carbazate, semi-carbazide, thiosemicarbazide, thiocarbazate, and aminoxy.

5. The method according to claim 4 , wherein the nucleophilic groups of the crosslinker are primary amine.

6. The method according to claim 1 , wherein the crosslinker is a dinucleophilic functional crosslinker.

7. The method according to claim 6 , wherein the crosslinker is selected from the group consisting of diamino hyaluronic acid tetrasaccharide, diamino hyaluronic acid hexasaccharide, diamino trehalose, diamino lactose, diamino maltose, diamino sucrose, chitobiose, and diamino raffinose.

8. The method according to claim 5 , wherein the crosslinker is an at least partially deacetylated hyaluronic acid.

9. The method according to claim 1 , wherein the crosslinking and grafting of step (c) provides amide bonds between glycosaminoglycan molecules and crosslinkers and between glycosaminoglycan molecules and graft chains.

10. The method according to claim 1 , wherein the mononucleophilic functional graft chain is a mononucleophilic functional carbohydrate.

11. The method according to claim 1 , wherein the mononucleophilic functional graft chain is an aminodextran and/or an aminocyclodextrin.

12. The method according to claim 11 , wherein the molar ratio of the aminodextran and/or aminocyclodextrin to disaccharide repeating units of the glycosaminoglycan is 0.1-50%.

13. The method according to claim 11 , wherein the aminodextran and/or aminocyclodextrin contain a linking group having an amino group, and wherein the linking group of the aminodextran and/or aminocyclodextrin forms an amide bond with an activated carboxyl group of the glycosaminoglycan.

14. The method according to claim 13 , wherein the linking group comprises a C1-6 alkyl.

15. The method according to claim 11 , wherein the aminodextran and/or aminocyclodextrin is an aminodextran.

16. The method according to claim 15 , wherein the aminodextran has an average molecular weight of less than 10 kDa.

17. The method according to claim 16 , wherein the aminodextran is covalently grafted to the activated glycosaminoglycan by single end-point attachment.

18. The method according to claim 15 , wherein the aminodextran is functionalized at the reducing end with a diamine.

19. The method according to claim 11 , wherein the aminodextran and/or aminocyclodextrin is an aminocyclodextrin.

20. The method according to claim 19 , wherein the aminocyclodextrin is constituted by 5-32 glucopyranoside units.

21. The method according to claim 20 , wherein the aminocyclodextrin is constituted by 6 glucopyranoside units (α-cyclodextrin).

22. The method according to claim 20 , wherein the aminocyclodextrin is constituted by 7 glucopyranoside units (β-cyclodextrin).

23. The method according to claim 20 , wherein the aminocyclodextrin is constituted by 8 glucopyranoside units (γ-cyclodextrin).

24. The method according to claim 20 , wherein the aminocyclodextrin is 6-aminocyclodextrin.

25. The method according to claim 1 , wherein at least 90% of the bonds between glycosaminoglycan molecules and crosslinkers and between glycosaminoglycan molecules and graft chains are amide bonds.

26. The method according to claim 1 , wherein less than 5% of the bonds between glycosaminoglycan molecules and crosslinkers and between glycosaminoglycan molecules and graft chains are ester bonds.

27. The method according to claim 1 , wherein the coupling agent is DMTMM.

28. The method according to claim 27 , wherein a ratio of the DMTMM to disaccharide repeating units of the glycosaminoglycan is in the range of 1-3.

29. The method according to claim 27 , wherein a ratio of the DMTMM to disaccharide repeating units of the glycosaminoglycan is in the range of 3-8.

Assignments (3)
CHANGE OF ADDRESS Recorded Jun 27, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 061113/0710 →
CHANGE OF NAME Recorded Dec 31, 2020
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 054899/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: NORD, LARS; MOJARRADI, HOTAN; OLSSON, JOHAN
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 053994/0424 →
Priority Claims (2)
EP 17178474 · Jun 28, 2017 · regional
EP 17178479 · Jun 28, 2017 · regional
Continuity (2)
Continuation PCTEP2018067257 · Jun 27, 2018
Related Publication 20200140626A1 · May 7, 2020
References Cited (7)
US 20180244807A1 · Karlsson · 2018 [cited by examiner]
US 20190023812A1 · Mojarradi · 2019 [cited by examiner]
WO WO0046252A1 · 2000 [cited by applicant]
WO WO2015181366A1 · 2015 [cited by applicant]
WO WO2016107834A1 · 2016 [cited by applicant]
WO WO2016192760A1 · 2016 [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/EP2018/067257, mailed on Sep. 26, 2018. [cited by applicant]